Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(05)79151-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse Events of Factor Xa Inhibitors in Pediatric Patients: A Meta-analysis and Pharmacovigilance Study.
Paediatr Drugs
January 2025
Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
Background: This study aimed to provide a comprehensive review of adverse events (AEs) associated with factor Xa (FXa) inhibitors in pediatric patients.
Methods: We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and the European Union Clinical Trials Register for English-language records from the establishment of the database up to October 17, 2023.
Development and validation of an interpretable machine learning model for predicting left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients.
PLoS One
January 2025
Department of Cardiovascular Medicine, The First Bethune Hospital of Jilin University, Changchun, Jilin Province, China.
Purpose: Left atrial thrombus or spontaneous echo contrast (LAT/SEC) are widely recognized as significant contributors to cardiogenic embolism in non-valvular atrial fibrillation (NVAF). This study aimed to construct and validate an interpretable predictive model of LAT/SEC risk in NVAF patients using machine learning (ML) methods.
Methods: Electronic medical records (EMR) data of consecutive NVAF patients scheduled for catheter ablation at the First Hospital of Jilin University from October 1, 2022, to February 1, 2024, were analyzed.
A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial.
JACC Cardiovasc Interv
January 2025
Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China. Electronic address:
Background: First-generation bioresorbable scaffolds (BRS) increased risks of stent thrombosis and adverse events. The Bioheart scaffold is a new poly-L-lactic acid-based BRS.
Objectives: This study sought to evaluate the efficacy and safety of the BRS in patients with coronary artery disease.
Net Clinical Benefit of 12-Month Over 3-Month Edoxaban in Cancer-Associated Isolated Distal Deep Vein Thrombosis.
JACC CardioOncol
December 2024
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.
The Impact of Genetic Polymorphism on Complication Development in Heart Failure Patients.
J Clin Med
December 2024
National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
Despite the high progress that has been made in the field of cardiology, the left ventricular assist device (LVAD) can still cause complications (thrombosis/bleeding) in heart failure (HF) patients after implantation. Complications develop due to the incorrect dose of antithrombotic therapy, due to the influence of the non-physiological shear stress of the device, and also due to inherited genetic polymorphisms. Therefore, the aim of our study is to identify the influence of the genetic polymorphisms on complication development in HF patients with implanted LVADs with prescribed antiplatelet therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!